Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00652015
Other study ID # EK 039/08
Secondary ID
Status Withdrawn
Phase N/A
First received March 31, 2008
Last updated September 22, 2015
Start date May 2008
Est. completion date May 2010

Study information

Verified date September 2015
Source RWTH Aachen University
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Observational

Clinical Trial Summary

In-Stent-Thrombosis is a rare but serious complication after implantation of stents during PTCA.


Description:

In this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (SAT), 40 late thromboses (LT)) and a control group of 80 patients having not developed a thrombosis will be compared.

The aim of this study is the establishment of diagnostic markers vor prediction of SAT (detection of CD39- and CD73-activity, respectively)and of LT (EPC-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients having developed an SAT or LT after stent implantation using PTCA

Exclusion Criteria:

- instabel coronary heart diseases,

- systemic autoimmune diseases,

- rheumatic diseases,

- tumors,

- impaired kidney or liver function,

- surgery within the last 3 months,

- pregnant or lactating women

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Patients With SAT or LT After Stent Implantation (PCI)
  • Thrombosis

Locations

Country Name City State
Germany RWTH University Hospital Aachen

Sponsors (1)

Lead Sponsor Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively. may 08 to may 2010 No